Chemoradiotherapy Clinical Trials

21 recruiting

Chemoradiotherapy Trials at a Glance

29 actively recruiting trials for chemoradiotherapy are listed on ClinicalTrialsFinder across 6 cities in 3 countries. The largest study group is Phase 2 with 16 trials, with the heaviest enrollment activity in Guangzhou, Beijing, and Beijing. Lead sponsors running chemoradiotherapy studies include Sun Yat-sen University, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, and Anhui Provincial Hospital.

Browse chemoradiotherapy trials by phase

Treatments under study

About Chemoradiotherapy Clinical Trials

Looking for clinical trials for Chemoradiotherapy? There are currently 21 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Chemoradiotherapy trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Chemoradiotherapy clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 29 trials

Recruiting
Phase 3

Consolidation of Toripalimab and Capecitabine After Chemoradiotherapy in ESCC

Esophageal CancerChemoradiotherapy
Sun Yat-sen University242 enrolled1 locationNCT07177794
Recruiting
Phase 2

Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer

ChemoradiotherapyLimited-stage Small Cell Lung Cancer (LS-SCLC)Toripalimab+1 more
Sun Yat-sen University47 enrolled1 locationNCT06719700
Recruiting

Compliance to Cervical Cancer Chemoradiation Guidelines: A Multicentric Implementation Audit and Resource Assessment Initiative of National Cancer Grid of India

Gynecologic CancersCervical Cancer ScreeningChemoradiotherapy+1 more
Tata Memorial Hospital618 enrolled2 locationsNCT07290972
Recruiting
Phase 2

Clinical Study of Thiopegfilgrastim for Preventing Bone Marrow Suppression in Thoracic Tumor Chemoradiotherapy

Thoracic NeoplasmsChemoradiotherapyMyelosuppression
Affiliated Hospital of Nantong University30 enrolled1 locationNCT07205536
Recruiting
Phase 2

Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell CarcinomaChemoradiotherapyToripalimab+2 more
Sun Yat-sen University69 enrolled1 locationNCT07086469
Recruiting
Phase 2

SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC

Rectal CancerRectal AdenocarcinomaTargeted Therapy+6 more
Ruijin Hospital104 enrolled1 locationNCT07198165
Recruiting

Symptoms Burden in Lung Cancer Patients Undergoing Definitive Chemoradiotherapy: Insights From Electronic Patient-Reported Outcomes

Lung CancerChemoradiotherapyPatient-Reported Outcomes (PRO)
Qian Chu100 enrolled1 locationNCT07131670
Recruiting
Phase 2

Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung Cancer

Non-small Cell Lung CancerTislelizumabConcurrent Chemoradiotherapy+2 more
Sun Yat-sen University80 enrolled1 locationNCT07086456
Recruiting
Phase 3

Neoadjuvant Immunotherapy Plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidative Immunotherapy for Locally Advanced Non-small Cell Lung Cancer

Neoadjuvant TherapyImmunotherapyLocally Advanced Non-Small Cell Lung Cancer+1 more
Sun Yat-sen University497 enrolled1 locationNCT06734702
Recruiting
Phase 2

A Prospective Phase II Study of Postoperative Concurrent Chemoradiotherapy in Patients With Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma (Icc)Adjuvant ChemoradiotherapyNarrow Margin+1 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences66 enrolled1 locationNCT07063888
Recruiting

Nutritional Status and Clinical Outcomes in Patients With Common Malignancies(NCOM)

CancerOncologyNutrition, Healthy+2 more
Xiaoqin Luo1,538 enrolled1 locationNCT06219083
Recruiting
Phase 2

Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer

Esophageal CancerSurgeryImmunotherapy+2 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences60 enrolled3 locationsNCT06421376
Recruiting

Investigation of Multi-omics Technique to Predict the Efficacy of Chemoradiotherapy Combined With Immunotherapy for r/m NPC

Nasopharyngeal CarcinomaMulti-omics TechniqueRecurrent and Metastatic Nasopharyngeal Carcinoma+1 more
Sun Yat-sen University50 enrolled1 locationNCT06197776
Recruiting
Phase 2Phase 3

Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer.

Radiotherapy Side EffectNeoadjuvant TherapyChemotherapy+8 more
National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos400 enrolled1 locationNCT06758830
Recruiting
Not Applicable

Oral Immunonutrition Therapy to Reduce Acute Toxicity After Neoadjuvant Chemoradiotherapy Pancreatic Cancer Patients

Pancreatic CancerNeoadjuvant ChemoradiotherapyImmunonutrition
Sun Yat-sen University98 enrolled2 locationsNCT06736678
Recruiting
Phase 1Phase 2

Chemoradiotherapy in Unresectable Esophageal Cancer

Esophageal CancerChemoradiotherapyAlbumin-bound Paxlitaxel+1 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences105 enrolled5 locationsNCT04278287
Recruiting
Phase 2

Sodium Glycididazole Reduces the Adverse Reactions of Concurrent Chemoradiotherapy

Chemoradiotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences40 enrolled1 locationNCT06667622
Recruiting
Phase 2Phase 3

Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC

Cervical CancerConcurrent ChemoradiotherapyNeoadjuvant Chemoimmunotherapy+1 more
Tongji Hospital440 enrolled12 locationsNCT06288373
Recruiting
Phase 2

Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma

Esophageal CancerImmunotherapyChemoradiotherapy+2 more
Zhejiang Cancer Hospital191 enrolled1 locationNCT06413342
Recruiting
Phase 2

Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients

Esophageal CancerChemotherapyImmunotherapy+2 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences55 enrolled1 locationNCT06429839